Quigley Anti-Viral Compound QR448(a) Successfully Prevents Transmission of Infectious Bronchitis i...(e other colony was not spray trea...),Health

spray treated.

-- At 3, 7, 10 and 14 days post treatment, 25 non-infected and 5 infected

birds were removed and their tracheas swabbed and tested for the

detection and transmission of virus from infected to non-infected birds.

-- It was demonstrated clearly that the QR448(a) treated colony showed a

statistically significant 5.5 fold reduction in transmission of virus at

14 days post-exposure [(P value, less than and/or equal to 0.1) One way

analysis of variance, Student's test] and a non-statistical 3 fold

reduction was observed at 10days post-exposure compared to the colony

that was not treated with QR448(a).

-- Serology, necropsy and clinical observations confirmed that other avian

pathogens and or immune-suppression had not influenced the results and

were consistent with exposure to a non-pathogenic vaccine virus.

-- Since QR448(a) has been shown previously to be effective against

pathogenic isolates of IBV and now against Arkansas vaccine virus, it is

expected that it will also limit transmission of pathogenic IBV in

broilers and thereby decrease the severity of the disease.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will issue an investigational new animal drug number or allow this compound to be marketed for IBV. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gum
'/>"/>